Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Revenues Shrink, Net Income Falls on Costs of Horizon Technology Buy

This article has been updated from a previous version to include additional information about the company's assets.

NEW YORK, Oct. 21 (GenomeWeb News) - Gene Logic earned $17 million in the third quarter ending on Sept. 30, down from total revenues of $17.7 million for the year-ago quarter, the company said today.

Net loss for the Gaithersburg, Md.-based company increased to $14. 6 million, from $10 million for the year-ago quarter based largely on a $9 million charge for purchased research and development associated with the acquisition of the Horizon technology from Millennium on July 23.

Gene Logic spent $631,000 on research and development in the quarter, up from $540,000 for the year-ago period.

The company reported cash and cash equivalents of $47 million on hand, and marketable securities of $60.1 million, down from $49 million and $63 million, respectively, on hand at Dec. 31, 2003.




The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.